lodigame 291 register

Long-term investing with a different perspective: Stocks of 5 companies with strong brands which have stood the test of time( ) late Wednesday handily beat Wall Street's targets for its fiscal fourth quarter. But its sales and earnings guidance for 2025 was below views. Adobe stock sank in extended trading. The digital media and marketing software firm earned an adjusted $4.81 a share on sales of $5.61 billion in the quarter ended Nov. 29. Analysts polled by FactSet had expected Q4 earnings of $4.67 a share on sales of $5.54 billion. On a year-over-year basis, Adobe earnings rose 13% while sales climbed 11%. For its fiscal first quarter, Adobe expects to earn an adjusted $4.98 a share on sales of $5.66 billion. That's based on the midpoint of its outlook. Analysts were modeling earnings of $4.95 a share on sales of $5.72 billion. For the full fiscal 2025, Adobe guided to adjusted earnings of $20.35 a share on sales of $23.43 billion. Analysts had been expecting earnings of $20.52 a share on sales of $23.78 billion. In its just-finished fiscal 2024, Adobe earned an adjusted $18.42 a share, up 15%, on sales of $21.51 billion, up 11%. Adobe Stock Falls After Q4 Report In after-hours trading on the , Adobe stock slid more than 7% to 506.50. During the regular session Wednesday, Adobe stock rose 0.5% to close at 549.93. Adobe's Creative Cloud, Document Cloud and Experience Cloud products are playing a "mission-critical role" in the AI economy, Chief Executive Shantanu Narayen said in a . Chief Financial Officer Dan Durn added, "Adobe's strategy, AI innovation and massive cross-cloud opportunity position us well for 2025 and beyond." Adobe stock has formed a with a of 587.75, according to charts.

Manchester City plunged deeper into trouble in the Champions League by losing 2-0 at Juventus on Wednesday, the latest setback in a scarcely believable run of poor results for the ailing English champions. City dropped to 22nd place in the 36-team standings, with only the top 24 advancing. Progressing to the next round of the new-look format looked a certainty before the season for a team that was European champion in 2023 and has won the last four Premier League titles. But not anymore as City manager Pep Guardiola battles injuries and an apparent loss of belief among his players. City has won just one of its last 10 matches in all competitions, with goals by Dušan Vlahović and Weston McKennie inflicting the latest defeat and igniting Juventus' qualification hopes. City midfielder Ilkay Gundogan described the team's problem as a “mental issue.” Opponents “are able to break our rhythm with the smallest of things,” Gundogan said. "They don’t even need to do much and it has such a big effect on us right now.” Barcelona jumped into second place in the league standings, behind Liverpool, and is guaranteed to advance after a 3-2 win at Borussia Dortmund. Raphinha and Ferran Torres, with two goals, scored for Barca. Arsenal beat Monaco 3-0 mainly thanks to two goals by Bukayo Saka to move into third place and be the highest of six teams on 13 points. The top eight qualify directly for the last 16 and the teams placed No. 9-24 go into a two-legged playoff. City has two games to save its faltering Champions League campaign and the first is against Paris Saint-Germain, another giant in trouble in 25th place — one spot out of the qualifying positions. Vlahović put Juventus ahead in the 53rd when he powered a header goalward straight at City goalkeeper Ederson, who could only parry the ball over his own line. Two American substitutes sealed the win for Juve, with McKennie volleying home from Timothy Weah's cross. Juventus moved into 14th place. Ferran Torres came off the bench to inspire Barcelona to a fifth win in six games and push Dortmund, last season's runner-up, out of the top eight. Torres came on in the 71st to replace Robert Lewandowski, who had a quiet game against his former club. Just four minutes later, Torres scored a goal on the rebound from Dani Olmo’s shot. Serhou Guirassy’s second goal of the game leveled the score at 2-2 but Torres scored again in the 85th off Lamine Yamal’s pass on the counter. Raphinha gave Barcelona the lead before Guirassy equalized from the penalty spot. Raphinha and Guirassy are tied for second place in the scoring chart on six goals, behind Lewandowski's competition-high seven. Arsenal secured a third straight home win without conceding in the league stage, with Saka scoring in the 34th and 78th minutes and sending in a shot that was turned into the net by substitute Kai Havertz in the 88th. Arsenal is ahead of Bayer Leverkusen, Aston Villa, Inter Milan, Brest and Lille on goal difference. Lille won 3-2 at home to Sturm Graz on Wednesday. Man City could sure do with Julian Alvarez at the moment. With a brilliant curling finish to open the scoring, the Argentina striker helped Atletico Madrid beat Slovan Bratislava 3-1 and provide a timely reminder of what City is missing after selling him for more than $100 million in August. Alvarez has 12 goals for the season, with four coming in the Champions League. Antoine Griezmann scored Atletico’s other two goals at Metropolitano stadium as the Spanish team climbed to 11th place after a 10th straight win in all competitions. When Lukasz Lakomy gave Young Boys the lead against Stuttgart, he ran toward the sideline and held up teammate Meschack Elia’s jersey as others gathered around him. The gesture was a tribute after Elia’s son died unexpectedly this week after a short illness. Elia wasn’t playing as he was on his way to his native Congo, where his son died, to be with his family. Both teams wore black armbands and there was a moment of silence before the game, which was won 5-1 by Stuttgart. Tammy Abraham scored an 87th-minute winner as AC Milan beat Red Star Belgrade 2-1 to move one point off the top eight. Milan lost Alvaro Morata and Ruben Loftus-Cheek to muscle injuries in the first half. Benfica’s five-match winning streak ended with a 0-0 home draw against Bologna, and Feyenoord had a 4-2 win over Sparta Prague. Steve Douglas is at https://twitter.com/sdouglas80 AP soccer: https://apnews.com/hub/soccerTop war-crimes court issues arrest warrants for Netanyahu and others in Israel-Hamas fighting

Germany Jointly With Denmark Transfers 15 More Leopard Tanks to Ukraine

Currency Exchange International, Corp. Announces Exchange Bank of Canada Appeal of FINTRAC's PenaltyBEIJING , Dec. 8, 2024 /PRNewswire/ -- At the end of 2024, we take a look back at the Chinese economy's performance this year. China's domestic GDP grew by 5.3 percent year-on-year in the first quarter, 4.7 percent in the second quarter and 4.6 percent in the third quarter this year, with an average growth rate of 4.8 percent in the first three quarters. Since September, as a package of incremental policies continues to yield its effects, China's economy maintains an upward trend. Overall, we are fully confident in achieving our economic growth goal this year. The country's economic performance has been hard-won. Externally, transformations around the world unseen in a century are unfolding at a greater pace, with global economic growth remaining sluggish, and the complexity, severity and uncertainty of the external environment on the rise. At home, domestic demand is insufficient, social expectations remain weak and there are difficulties associated with structural adjustments. The situation is severe and complex, and the task is difficult and weighty. However, under the strong leadership of the Communist Party of China Central Committee with Comrade Xi Jinping at its core, Chinese localities and government agencies are more confident and are taking solid steps to deliver outcomes. The results underscore that "fundamentals of the Chinese economy, and favorable conditions such as a vast market, strong economic resilience and great potential remain unchanged." Huge market, vast space Markets are the scarcest resource. The modernization achieved by 1.4 billion Chinese people has resulted in the addition of a new super-large market larger than those of all developed countries combined. The new development paradigm will enable China to fully unlock its market potential and create greater demand for other countries. With a new car rolling off production line on November 14 , China's annual production of new energy vehicles (NEVs) surpassed the 10 million milestone, becoming the first country in the world to do so. Behind the number is China's robust supply and demand. In the first 10 months, China's production and sales of NEVs grew by 33 percent and 33.9 percent year-on-year, respectively. China continues to take the lead in the electrification and intelligence transformation of the automotive industry, which is attributed to the supply, policy support and demand advantage in the ultra-large market. Markets bring valuable business opportunities. Take cars for example. By the end of June, China had 345 million cars, but the country's car ownership level per 1,000 residents is less than half of that in developed countries. Additionally, China's NEV ownership is only 24.72 million, which means continuous demand in the future. Markets breed competition advantages. China's vast market contributes to the formation of "economy of scale" and "economy of scope," which generates greater profits for enterprises and reduces innovations costs, and also helps provide a large number of application scenarios and boost the large-scale application of innovations. China leads the world in batteries, motors and electronic control technologies, while its intelligent cockpits and intelligent driving are internationally advanced. Thanks to the benign interactions between supply and demand, the industrialization of new technologies and new products is speeding up. Strong resilience, solid basis Resilience strengthens self-belief. China has come to where it is today after overcoming all kinds of difficulties and challenges. Foreign trade is an important barometer in this regard. In the first 10 months of the year, China's foreign goods trade rose by 5.2 percent year-on-year to reach a new high compared with the same period historically. The improvement in the quality and efficiency of the country's foreign trade against the backdrop of shrinking external demand reflects China's economic resilience. This resilience originates from China's solid manufacturing basis and industrial chain advantages. "We could not do what we do without them," Apple CEO Tim Cook said of Chinese suppliers during his third visit to the Chinese mainland this year, as over 80 percent of Apple's 200 major suppliers have set up factories in China . China has the world's most comprehensive industrial categories and a well-rounded industrial system, with the scale of manufacturing industry ranking top for 14 consecutive years. The high-end, intelligent and green development of the manufacturing sector continues to strengthen the stability of the country's industrial and supply chain. In the first three quarters, the manufacturing industry contributed 32.2 percent to the country's economic growth, up 11.2 percentage points. China moved up to 11th place in the ranking of the world's most innovative economies. The basis is solid, and risks and challenges are not to be feared. Resilience also comes from excellent policy adjustments. The nation has been strengthening counter-cyclical adjustments, accelerating the implementation of major national strategies and the development of securities capabilities in key areas while supporting large-scale equipment upgrades and trade-in policies for consumer goods with robust measures, boosting the stabilization of the property market and galvanizing the capital market. The government has also put forward a package of measures to dissolve local government debt risks. This year, a series of existing policies continue to produce effects and incremental policies are being effectively implemented, jointly helping the economy stabilize. Vast potential, strong momentum China's economy has vast potential and many advantages and favorable conditions for sustaining long-term development momentum. China has been the world's second-largest economy for many years, but still has vast development potential in terms of per capita and structure. China's per capita GDP remains relatively low, and the country's amount of infrastructure per capita is only 20-30 percent of that of developed countries. In 2023, China's urbanization rate, which measures the ratio of permanent urban residents relative to the total population, reached 66.2 percent by the end of 2023. Estimates show that each percentage point increase in the urbanization rate could drive 1 trillion yuan ( $137.55 billion ) in investment. Currently, both China's fiscal deficit ratio and government debt ratio are low, and the country's policy toolbox remains well-stocked. The potential also lies in elementary resources. China's human resources in science and technology ranked first in the country and the average length of education received by new entrants into the workforce has increased to 14 years, turning the demographic dividend into a talent dividend. In addition, overall sufficient social capitals, vast room for the highly efficient use of land and the vast unleashing of the potential of digital elements provide solid foundational support. This potential also comes from the huge market. The country's population of over 1.4 billion and middle-income population of over 400 million support a large-scale, diverse and huge domestic market. Accelerating the building of a unified national market will improve overall economic operation efficiency and continuously unleash the potential of domestic demand. Overall, China is a country with vast territory, a large population and unbalanced and uncoordinated development. This is a shortcoming, but also represents potential and a driving force for future development. Sparking vitality and building synergy through reform is essential to continuously unleashing development potential. From implementing regulations for fair competition reviews, accelerating the legislative process of the law on the promotion of the private economy and formulating normal communication mechanisms between governments and enterprises, to releasing a new national negative list for foreign investment and removing all market access restrictions for foreign investors in the manufacturing sector, China's reforms in key fields continue to deepen this year and high-level opening-up advances in an in-depth way. The third plenary session of the 20th Central Committee of the Communist Party of China adopted the Resolution of the CPC Central Committee on Further Deepening Reform Comprehensively to Advance Chinese Modernization. Driven by reform of the economic system, China is correspondingly boosting reform in other fields, and the internal development momentum and vitality will continue to strengthen. Reviewing allows a clear understanding of the situation and better moving forward. While some major economies experience low growth rates and high inflation this year, China is expected to achieve its economic growth target of around 5 percent, and continue to contribute around 30 percent to world economic growth. This stable performance underlines the fact that China's economy will continue to remain on a positive trajectory over the long run. The story was originally published on the front page of the People's Daily on December 8, 2024 View original content: https://www.prnewswire.com/news-releases/global-times-peoples-daily-article-says-favorable-conditions-for-chinas-economic-development-remain-unchanged-302325568.html SOURCE Global TimesMixed day for global stocks as market hopes for 'Santa Claus rally'

MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com . About CVRx, Inc. CVRx is focused on the development and commercialization of the BarostimTM System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com . Investor Contact: Mark Klausner or Mike Vallie ICR Healthcare 443-213-0501 ir@cvrx.com Media Contact: Laura O’Neill Finn Partners 402-499-8203 laura.oneill@finnpartners.com

Overachievers collide when Georgia Tech, Vandy play in Birmingham

Luigi Mangione, 26, was charged with murdering UnitedHealthcare CEO Brian Thompson. Following his arrest, various claims about him circulated online, including speculation about an online manifesto that allegedly explained his motive for the killing. The post, attributed to "LM" on the blog site Substack, is titled “The Allopathic Complex and Its Consequences" and has been shared in various social media posts crediting Mangione as the author. This is allegedly Luigi Mangione’s manifesto. pic.twitter.com/uOFsGA6Nki VERIFY reader Tony texted us asking if the manifesto published to Substack is real. THE QUESTION Is the viral online post on Substack appearing to be written by Luigi Mangione real? THE SOURCES THE ANSWER No, the viral online post published to Substack appearing to be written by Luigi Mangione isn’t real. WHAT WE FOUND Luigi Mangione had a three-page document with him when he was arrested that police say speaks to his alleged motive at the time of the killing, but claims the manifesto posted online was authored by Mangione are false. VERIFY analyzed excerpts of the handwritten document and found it doesn't match any of the language in the fake online manifesto. Substack also said it removed the account because it violates the platform’s content guidelines, “which prohibit impersonation.” During a Dec. 9 press conference , New York Police Commissioner Jessica Tisch said the handwritten document Mangione had on his person when arrested “speaks to both his motivation and mindset.” When asked if the handwritten document was posted online, the New York Police Department’s Chief of Detectives Joseph Kenny said, “Don’t know if it's online. As of right now, it's a handwritten three-page document.” While police haven’t publicly released the handwritten document, excerpts have been reported by various news outlets such as the Associated Press , The New York Times and CBS . According to these reports, the document was either independently reviewed or described to reporters by sources close to the investigation. The New York Times summarized the excerpts they reviewed, saying the handwritten document called Thompson’s killing a “symbolic takedown” of the healthcare industry and also referenced corruption and “power games.” CBS reported Mangione criticized the disparity between U.S. healthcare costs and life expectancy rates. We compared the quoted excerpts from the reports to the Substack manifesto posted online and found none of the language from the handwritten document appears in the manifesto. The fake manifesto also lacks any reference to healthcare costs or life expectancy rates. Substack didn’t provide details on when the account was removed from the platform, but VERIFY was able to use archived pages captured on The Wayback Machine to determine the account was likely created while Mangione was in police custody. The Wayback Machine allows users to view and access snapshots, or screenshots, of websites. This screenshot archive from The Wayback Machine of the Substack account attributed to Mangione was captured at 9:43 p.m. ET on Dec. 9. Text on the Substack page archived indicates it was created about two hours earlier, during the time Mangione would have been in custody. At around 1:45 p.m. on Dec. 9 , the NYPD announced Mangione had been arrested as a person of interest in Thompson’s murder. He was arraigned on Dec. 9 around 6:30 p.m., according to court records. Related Articles The VERIFY team works to separate fact from fiction so that you can understand what is true and false. Please consider subscribing to our daily newsletter , text alerts and our YouTube channel . You can also follow us on Snapchat , Instagram , Facebook and TikTok . Learn More » Follow Us Want something VERIFIED? Text: 202-410-8808Ukraine must be in strong position for negotiations, Starmer says

None

ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 [email protected] SOURCE TransMedics Group, Inc.The final matchup of Week 16 of the NFL season pits the Green Bay Packers against the New Orleans Saints on Monday, Dec. 23 at Lambeau Field in Green Bay, Wis. The game is scheduled to start at 8:15 p.m. EST and will be broadcast on ABC, ESPN and ESPN Deportes . Fans looking to watch this NFL game can do so for free by using FuboTV , which offers RedZone, a free trial and $30 off on your first month, or DirecTV Stream , which also offers a free trial and RedZone. SlingTV has promotional offers available, and NFL+ airs all local market games. The 10-4 Packers are only separated by one loss from the Washington Commanders who are currently the seven seed in the NFC playoff picture at 10-5. The 5-9 Saints have already been eliminated from playoff contention, but can still be a spoiler both this week and Week 18 when they face the 8-7 Tampa Bay Buccaneers. Who: New Orleans Saints vs. Green Bay Packers When : Monday, Dec. 23 at 8:15 p.m. EST Where : Lambeau Field in Green Bay, Wis. Stream : fuboTV (free trial) ; or Sling ; DirecTV Stream (free trial) or NFL+ More College Football What is FuboTV? FuboTV is an internet television service that offers more than 200 channels across sports and entertainment including Paramount+ with SHOWTIME . From the UEFA Champions League to the WNBA to international sports tournaments, plenty of options are available on FuboTV, which offers new customers a free trial and $30 off the first month. What is DirecTV Stream? DirecTV Stream offers practically everything DirecTV provides, except for a remote and a streaming device to connect to your television. Sign up now and get three free months of premium channels including MAX , Paramount+ with SHOWTIME and Starz. What is SlingTV? SlingTV offers a variety of live programming ranging from news and sports and starting as low as $20 a month for your first month. Subscribers also get a month of DVR Plus free if they sign up now. Choose from various sports packages without long-term contracts and with easy cancelation. What is NFL+? NFL+ and NFL+ Premium allow fans access to the most NFL content available online. From game replays, coaches' film and all-22 field angles of the games to NFL Network original programming, NFL+ and NFL + Premium allow fans to stay fully locked in with every NFL team no matter where you are in the country. RELATED CONTENT: Netflix is airing 2 NFL games on Christmas Day. Here’s what to know By JOE REEDY AP Sports Writer Netflix will have one of its biggest days Wednesday since the site launched in 1998 when it airs two NFL games for the first time. “NFL Christmas Gameday on Netflix” begins with a two-hour pregame show at 11 a.m., before Pittsburgh hosts Kansas City. Baltimore faces Houston in the second game. The streaming giant agreed to a three-year contract in May to carry Christmas Day games. Where will the games be available? Netflix’s 282.3 million subscribers in over 190 countries will be able to stream the games, marking the first time one outlet has distributed an NFL game globally. Netflix will have the games available in five languages — English, French, Spanish, Portuguese, and German. The games will also air on CBS affiliates in Kansas City, Pittsburgh, Baltimore and Houston. NFL policy dictates that games on cable or being exclusively streamed must also be on an over-the-air station in the competing teams' markets. It will also be available on mobile devices in the U.S. for those who have NFL+. Why is the NFL putting Christmas Day games on a streaming platform? The biggest reason is money. The league is getting $150 million from Netflix for the two games this season. It also continues the NFL’s moves into streaming — Thursday night games are in their third season on Amazon Prime Video and the “Sunday Ticket” package moved to YouTube TV last year. But Christmas is on a Wednesday when games usually aren’t played. That’s true, but the league wasn’t about to give up Christmas after seeing the ratings. Last year’s three games averaged 28.68 million viewers. The early afternoon contest between the Las Vegas Raiders and Chiefs led the way, averaging 29.48 million. The Chiefs, Steelers, Ravens and Texans played on Saturday, giving them the same turnaround they would have if they played on Sunday and then Thursday. What is at stake for the teams playing? All four have clinched playoff spots in the AFC, but seeding remains up for grabs. Kansas City (14-1) can clinch the top seed — which would mean a first-round bye and home field throughout the playoffs — with a win over the Steelers. Pittsburgh and Baltimore are tied atop the AFC North at 10-5, with the Steelers holding the tiebreaker due to a better conference record. Houston (9-6) has wrapped up the AFC South and holds the fourth seed. Has Netflix fixed its streaming problems from the Jake Paul-Mike Tyson fight? Netflix hopes so. Brandon Riegg, Netflix’s vice president of nonfiction series and sports, said the system was stress tested, and then some, during the Nov. 14 bout, along with internet service providers reporting they were also overwhelmed by the surge that occurred before and during the fight. The bout peaked at 65 million concurrent streams, including 38 million concurrent streams in the United States. According to the website Down Detector, nearly 85,000 viewers logged problems with outages or streaming leading up to and during the fight. Could there be the same number streaming the games that there were during the fight? Possible? Yes. Likely? No. The largest audience for a streamed-exclusive NFL game was 23 million on Peacock for last season’s AFC wild-card game between the Miami Dolphins and Chiefs. Nielsen will measure the ratings for the Christmas Day games, with early numbers expected late afternoon on Thursday. When could there be surge in demand on Wednesday? It will probably beat kickoff for both games, but especially around 5:45 p.m. EST. That would be near halftime of the Ravens-Texans game, and when Beyoncé will be performing. What other celebrities will appear? Mariah Carey will kick off the day with a taped performance of “All I Want for Christmas is You.” There is no word if Taylor Swift will make the trip to Pittsburgh to watch her boyfriend, Chiefs tight end Travis Kelce. Swift has been spending time in Kansas City since she wrapped up her Eras Tour two weeks ago. How many Christmas games will Netflix carry in the next two seasons? The NFL will have at least two games on Dec. 25 in 2025 and ’26, with Netflix slated to have at least one each year. Amazon Prime Video will have a night game with Christmas on a Thursday next year. Does Netflix have an interest in other sports? Netflix’s worldwide partnership with World Wrestling Entertainment will begin on Jan. 6 when “Monday Night Raw” moves to the streaming service. On Friday, Netflix secured the U.S. rights for the 2027 and 2031 FIFA Women’s World Cup. The Associated Press contributed to this article.